nfluenza
negativestrand
rna
viru
belong
famili
orthomyxovirida
consist
genera
influenza
influenza
b
influenza
c
thogoto
virus
protein
influenza
encod
rna
gene
segment
influenza
virus
wide
distribut
natur
infect
wide
varieti
bird
mammal
influenza
viru
subtyp
classifi
basi
antigen
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
ha
na
subtyp
known
exist
infect
aquat
bird
infect
waterfowl
associ
clinic
diseas
rel
subtyp
influenza
virus
caus
sustain
outbreak
diseas
human
popul
influenza
virus
ha
na
subtyp
circul
human
popul
centuri
virus
appear
circul
replac
virus
virus
appear
replac
virus
remain
circul
human
popul
virus
reappear
human
popul
continu
cocircul
virus
current
influenza
epidem
winter
caus
influenza
influenza
b
virus
addit
season
influenza
epidem
influenza
pandem
occur
period
influenza
pandem
occur
influenza
strain
novel
ha
subtyp
without
novel
na
subtyp
appear
spread
human
popul
littl
immun
novel
ha
centuri
pandem
occur
associ
substanti
ill
death
pandem
spanish
flu
caus
influenza
viru
subtyp
respons
million
death
worldwid
asian
influenza
pandem
virus
appear
influenzaassoci
excess
death
estim
million
worldwid
influenza
pandem
start
hong
kong
caus
viru
pandem
viru
na
viru
replac
novel
ha
pandem
much
less
sever
previou
pandem
estim
influenzaassoci
excess
death
million
preexist
immun
na
pandem
influenza
viru
may
partial
explain
pandem
less
sever
preced
pandem
although
avail
penicillin
macrolid
may
also
contribut
predict
next
influenza
pandem
occur
influenza
viru
subtyp
caus
forecast
sever
next
influenza
pandem
differ
predict
death
base
model
use
model
base
pandem
project
million
excess
death
worldwid
meltzer
colleagu
estim
absenc
effect
intervent
unit
state
alon
next
influenza
pandem
could
caus
excess
death
hospit
well
ten
million
outpati
visit
addit
ill
scenario
econom
impact
influenza
pandem
would
sever
econom
cost
due
death
ill
hospit
unit
state
alon
exclud
disrupt
commerc
societi
would
billion
recent
outbreak
asia
million
bird
die
cull
period
countri
thailand
vietnam
estim
decreas
gross
domest
product
gdp
result
poultri
farm
loss
billion
respect
total
estim
loss
gdp
asia
billion
accord
sourc
addit
effect
local
poultri
product
commerc
intern
trade
travel
would
undoubtedli
suffer
influenza
pandem
aquat
bird
reservoir
known
subtyp
influenza
virus
pool
pandem
influenza
virus
aris
avian
influenza
ai
virus
introduc
human
popul
reassort
circul
human
influenza
virus
directli
infect
human
wide
believ
infect
human
ai
viru
would
undergo
reassort
human
influenza
viru
intermedi
mammalian
speci
acquir
necessari
characterist
effici
transmiss
replic
human
last
year
direct
transmiss
ai
virus
bird
human
report
sever
occas
caus
wide
spectrum
diseas
rang
mild
febril
respiratori
ill
infect
conjunct
case
influenza
infect
sever
diseas
death
seen
current
outbreak
asia
detail
case
given
tabl
gene
segment
influenza
virus
isol
human
patient
deriv
ai
virus
evid
reassort
human
influenza
virus
surveil
studi
bird
hong
kong
show
ai
virus
cocircul
poultri
market
hong
kong
time
ai
outbreak
creat
favor
condit
reassort
ai
virus
becom
widespread
domest
chicken
asia
sinc
addit
ai
subtyp
isol
duck
gees
region
suggest
wide
distribut
vaccin
pandem
influenza
avian
host
data
phylogenet
studi
led
hypothesi
hong
kong
virus
acquir
ha
gene
viru
gene
encod
na
atealhong
like
viru
circul
terrestri
poultri
data
also
suggest
ai
virus
circul
region
like
sourc
intern
protein
gene
virus
continu
circul
bird
southern
china
outbreak
human
case
end
depopul
poultri
market
hong
kong
action
may
avert
influenza
pandem
precursor
virus
howev
continu
circul
region
highli
pathogen
virus
reemerg
new
human
infect
identifi
continu
report
date
reemerg
highli
pathogen
ai
virus
asia
rais
concern
potenti
pandem
result
augment
level
prepared
eventu
pandem
prepared
plan
unit
state
publish
novemb
wwwhh
govpandemicfluplan
two
intervent
strategi
could
prevent
lessen
sever
emerg
influenza
pandem
vaccin
use
antivir
drug
use
antivir
compound
discuss
anoth
articl
issu
focu
challeng
face
develop
pandem
influenza
vaccin
prepar
test
librari
vaccin
seed
virus
although
next
influenza
pandem
could
possibl
caus
differ
avian
reassort
viru
highli
pathogen
ai
viru
circul
asia
current
vaccin
develop
activ
larg
focus
virus
subtyp
event
asia
underscor
urgent
need
gener
candid
vaccin
evalu
human
ignor
ai
virus
subtyp
would
imprud
ai
virus
presum
pandem
potenti
central
pandem
prepared
plan
effect
vaccin
thwart
spread
pandem
viru
prevent
ill
death
associ
novel
virul
strain
principl
behind
gener
human
influenza
vaccin
elicit
protect
antibodi
direct
primarili
ha
major
protect
antigen
viru
induc
neutral
antibodi
although
major
advanc
understand
biolog
ecolog
ai
virus
made
sinc
human
infect
first
report
mani
year
experi
much
accumul
knowledg
immun
human
influenza
virus
gap
remain
understand
immun
ai
virus
tabl
fill
gap
vital
develop
vaccin
protect
human
popul
studi
use
inactiv
vaccin
subtyp
ai
purifi
recombin
ha
demonstr
vaccin
poorli
immunogen
comparison
epidem
human
influenza
strain
subtyp
exampl
inactiv
vaccin
avian
influenza
subtyp
requir
dose
administr
adjuv
achiev
desir
level
neutral
antibodi
tabl
precis
antigen
properti
nascent
pandem
strain
predict
avail
vaccin
may
poorli
antigen
match
pandem
viru
practic
consider
hurdl
pandem
influenza
vaccin
develop
also
overcom
manufactur
capac
abil
candid
vaccin
strain
grow
well
egg
biolog
safeti
contain
parent
strain
vaccin
develop
problem
address
addit
vulner
section
popul
may
seen
yearli
influenza
epidem
make
plan
target
certain
popul
group
vaccin
difficult
best
reason
time
next
pandem
must
use
judici
develop
clinic
test
candid
vaccin
interpandem
period
must
use
explor
optim
scientif
manufactur
regulatori
clinic
research
strategi
develop
vaccin
effect
pandem
influenza
vaccin
avail
soon
possibl
event
pandem
end
laboratori
infecti
diseas
nation
institut
allergi
infecti
diseas
niaid
nation
institut
health
nih
embark
program
develop
candid
vaccin
prevent
influenza
pandem
caus
ai
virus
vaccin
seed
virus
gener
base
live
attenu
coldadapt
influenza
viru
vaccin
develop
maassab
colleagu
univers
michigan
use
basi
flumist
vaccin
medimmun
inc
gaithersburg
md
usa
licens
unit
state
person
year
age
prevent
interpandem
influenza
principl
develop
vaccin
safeti
efficaci
studi
conduct
human
review
elsewher
vaccin
seed
viru
develop
strategi
exclus
live
attenu
vaccin
similar
studi
inactiv
vaccin
differ
ai
subtyp
initi
goal
research
program
establish
proof
principl
coldadapt
aa
ca
viru
bear
ai
viru
ha
na
gene
infecti
immunogen
safe
human
therefor
potenti
use
control
pandem
influenza
observ
efficaci
live
attenu
vaccin
human
interpandem
influenza
togeth
find
date
inactiv
subunit
ai
vaccin
suboptim
immunogen
human
strongli
suggest
use
live
vaccin
pandem
influenza
worth
explor
live
attenu
ai
vaccin
might
requir
fewer
dose
might
provid
broader
immun
respons
inactiv
subunit
vaccin
live
attenu
influenza
candid
vaccin
bear
intern
gene
aa
ca
donor
viru
attenu
gene
protect
ha
na
gene
human
virus
studi
extens
human
licens
gener
use
vaccin
safe
infecti
immunogen
nontransmiss
genet
stabl
efficaci
review
reason
propos
live
attenu
vaccin
would
rapidli
induc
protect
immun
respons
requir
experiment
verif
human
pandem
influenza
vaccin
candid
gener
plasmidbas
revers
genet
shown
figur
panel
review
techniqu
allow
infecti
viru
recov
cell
approv
use
human
vaccin
develop
socal
qualifi
cell
cell
cotransfect
plasmid
encod
influenza
gene
segment
gener
recombin
virus
contain
ha
na
gene
ai
virus
intern
gene
segment
aa
ca
viru
revers
genet
allow
modif
known
virul
motif
ha
na
gene
remov
multibas
amino
acid
cleavag
site
motif
ha
gene
highli
pathogen
ai
strain
associ
virul
bird
advantag
revers
genet
select
system
need
deriv
appropri
reassort
virus
background
parent
virus
addit
plasmid
encod
gene
attenu
vaccin
donor
strain
avail
ha
na
gene
need
clone
vaccin
sever
vaccin
candid
develop
use
techniqu
potenti
obstacl
appli
revers
genet
approach
includ
need
qualifi
cell
viru
product
intellectu
properti
techniqu
howev
long
ha
na
gene
segment
modifi
gene
reassort
investig
pandem
vaccin
gener
genet
reassort
shown
figur
panel
b
candid
pandem
vaccin
gener
use
techniqu
live
attenu
vaccin
must
abl
replic
level
elicit
protect
immun
respons
without
caus
diseas
host
balanc
infect
level
attenu
immunogen
must
vaccin
pandem
influenza
achiev
therefor
next
pandem
must
evalu
human
safeti
infect
immunogen
phenotyp
stabil
live
attenu
influenza
candid
vaccin
type
vitro
vivo
studi
perform
clinic
trial
human
initi
addit
standard
safeti
test
list
tabl
vitro
studi
perform
confirm
genom
sequenc
vaccin
virus
coldadapt
temperaturesensit
phenotyp
vaccin
virus
confirm
vitro
tissu
cultur
attenu
phenotyp
vaccin
candid
must
test
appropri
anim
model
critic
step
evalu
vaccin
candid
select
model
restrict
replic
vaccin
viru
convincingli
demonstr
comparison
wildtyp
parent
viru
sinc
predict
ai
virus
differ
subtyp
behav
differ
anim
speci
anim
model
viru
subtyp
develop
use
rodent
model
eg
mice
hamster
explor
use
ferret
model
investig
well
although
limit
avail
influenzaseroneg
ferret
facil
highli
pathogen
wildtyp
ai
virus
evalu
ferret
make
studi
logist
practic
difficult
assess
larg
number
candid
vaccin
addit
higher
bodi
temperatur
ferret
may
confound
interpret
studi
replic
temperaturesensit
virus
assess
vaccin
virus
may
also
requir
evalu
standard
offic
intern
de
world
organ
anim
health
intraven
pathogen
test
chicken
confirm
highli
pathogen
chicken
pose
threat
poultri
industri
requir
guid
nation
agricultur
author
immunogen
dose
respons
antibodi
respons
kinet
efficaci
studi
also
carri
appropri
anim
model
clinic
trial
past
experi
live
attenu
vaccin
interpandem
human
influenza
indic
live
viru
vaccin
may
great
potenti
use
vaccin
pandem
spread
influenza
high
level
immunogen
immunolog
naiv
person
abil
rapidli
induc
immun
ie
within
first
day
vaccin
contribut
cellular
immun
respons
control
ai
viru
infect
remain
determin
examin
context
live
attenu
vaccin
respons
may
valuabl
influenza
pandem
vaccin
may
protect
sever
ill
death
even
complet
antigen
match
emerg
strain
sinc
live
attenu
viru
vaccin
base
aa
ca
donor
viru
licens
food
drug
administr
gener
use
healthi
person
year
age
infrastructur
manufactur
character
live
attenu
viru
vaccin
exist
avail
manufactur
capabl
live
attenu
viru
vaccin
make
feasibl
initi
project
collabor
industri
develop
seed
virus
live
attenu
vaccin
influenza
virus
pandem
potenti
overal
plan
includ
follow
step
gener
set
live
attenu
virus
bear
ha
accompani
na
found
wildtyp
viru
gener
novel
combin
ha
na
protein
attenu
aa
ca
donor
viru
background
prepar
qualif
clinic
lot
pandem
vaccin
candid
evalu
safeti
infect
immunogen
phenotyp
stabil
candid
vaccin
human
storag
human
sera
obtain
vaccine
determin
antigen
related
vaccin
administ
studi
particip
actual
newli
emerg
pandem
virus
storag
seed
virus
manufactur
vaccin
prevent
diseas
caus
pandem
virus
emerg
thu
vaccin
manufactur
initi
pretest
virus
without
delay
even
seed
viru
match
pandem
strain
vaccin
viru
exact
match
gener
dose
immunogen
data
previou
vaccin
studi
guid
use
aa
ca
reassort
viru
safe
attenu
infecti
human
use
challeng
viru
assess
vaccin
efficaci
live
inactiv
influenza
viru
vaccin
major
concern
associ
use
live
attenu
influenza
vaccin
bear
gene
deriv
ai
viru
risk
reassort
vaccin
viru
circul
influenza
viru
reassort
could
result
novel
subtyp
influenza
could
spread
human
popul
although
event
may
concern
face
widespread
diseas
pandem
strain
influenza
would
clearli
unfavor
outcom
threaten
pandem
materi
clinic
trial
human
live
attenu
pandem
vaccin
candid
perform
care
plan
execut
inpati
studi
risk
reassort
must
care
consid
public
health
author
decis
made
introduc
live
attenu
vaccin
threaten
pandem
use
everi
avail
option
develop
vaccin
may
use
influenza
pandem
critic
recent
event
asia
led
intens
plan
prepar
potenti
global
influenza
pandem
vaccin
develop
critic
part
prepared
recent
studi
use
mathemat
model
studi
potenti
intervent
strategi
predict
local
prevaccin
vaccin
efficaci
pandem
strain
could
enhanc
effect
antivir
prophylaxi
prevent
spread
viru
product
establish
proof
principl
candid
live
inactiv
vaccin
ai
ha
na
protein
interpandem
period
could
save
valuabl
time
event
pandem
studi
also
provid
inform
biolog
ai
virus
immun
respons
human
